Literature DB >> 7649980

Amyloid beta-protein inhibits ubiquitin-dependent protein degradation in vitro.

L Gregori1, C Fuchs, M E Figueiredo-Pereira, W E Van Nostrand, D Goldgaber.   

Abstract

Intraneuronal accumulation of ubiquitin conjugates in inclusion bodies and neurofibrillary tangles is a pathological feature of neurodegenerative disorders such as Alzheimer's disease and Down's syndrome and of normal aging of the brain. Amyloid beta-protein (A beta) and its precursor are found in neurofibrillary tangle-containing neurons. A beta is the major component of extracellular plaques. We showed that A beta acts as an inhibitor of the ubiquitin-dependent protein degradation in vitro. We examined the effect of A beta on the steps of this proteolytic pathway that contribute to the level of ubiquitin conjugates in the cell. Neither conjugate formation nor conjugate deubiquitination was affected by the presence of A beta. However, A beta significantly reduced the rate of conjugate degradation. Our results indicate that A beta interacts with the proteolytic step of the ubiquitin degradative pathway. Since this step is performed by the 26 S proteasome, the effect of A beta on the catalytic core of this proteolytic complex, the 20 S proteasome, was determined. We found that A beta selectively inhibits the chymotrypsin-like activity of the 20 S proteasome. Under pathological conditions in the affected neuron, A beta could interfere with ubiquitin-dependent degradation by inhibiting the 26 S proteasome activity. This finding may explain the origin of the accumulation of ubiquitin conjugates.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7649980     DOI: 10.1074/jbc.270.34.19702

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  63 in total

1.  Studying protein degradation pathways in vivo using a cranial window-based approach.

Authors:  Vivek K Unni; Darius Ebrahimi-Fakhari; Charles R Vanderburg; Pamela J McLean; Bradley T Hyman
Journal:  Methods       Date:  2010-12-25       Impact factor: 3.608

2.  Proteasome inhibition and aggresome formation in sporadic inclusion-body myositis and in amyloid-beta precursor protein-overexpressing cultured human muscle fibers.

Authors:  Pietro Fratta; W King Engel; Janis McFerrin; Kelvin J A Davies; Sharon W Lin; Valerie Askanas
Journal:  Am J Pathol       Date:  2005-08       Impact factor: 4.307

3.  Curcumin and its derivatives: their application in neuropharmacology and neuroscience in the 21st century.

Authors:  Wing-Hin Lee; Ching-Yee Loo; Mary Bebawy; Frederick Luk; Rebecca S Mason; Ramin Rohanizadeh
Journal:  Curr Neuropharmacol       Date:  2013-07       Impact factor: 7.363

4.  Parkin mediates beclin-dependent autophagic clearance of defective mitochondria and ubiquitinated Abeta in AD models.

Authors:  Preeti J Khandelwal; Alexander M Herman; Hyang-Sook Hoe; G William Rebeck; Charbel E-H Moussa
Journal:  Hum Mol Genet       Date:  2011-03-04       Impact factor: 6.150

5.  Misfolded PrP impairs the UPS by interaction with the 20S proteasome and inhibition of substrate entry.

Authors:  Pelagia Deriziotis; Ralph André; David M Smith; Rob Goold; Kerri J Kinghorn; Mark Kristiansen; James A Nathan; Rina Rosenzweig; Dasha Krutauz; Michael H Glickman; John Collinge; Alfred L Goldberg; Sarah J Tabrizi
Journal:  EMBO J       Date:  2011-07-08       Impact factor: 11.598

Review 6.  Type 2 diabetes as a protein misfolding disease.

Authors:  Abhisek Mukherjee; Diego Morales-Scheihing; Peter C Butler; Claudio Soto
Journal:  Trends Mol Med       Date:  2015-05-18       Impact factor: 11.951

7.  Alzheimer's Disease is Driven by Intraneuronally Retained Beta-Amyloid Produced in the AD-Specific, βAPP-Independent Pathway: Current Perspective and Experimental Models for Tomorrow.

Authors:  Vladimir Volloch; Bjorn Olsen; Sophia Rits
Journal:  Ann Integr Mol Med       Date:  2020

8.  Intraneuronal dopamine-quinone synthesis: a review.

Authors:  D Sulzer; L Zecca
Journal:  Neurotox Res       Date:  2000-02       Impact factor: 3.911

9.  The induction of HIF-1 reduces astrocyte activation by amyloid beta peptide.

Authors:  David Schubert; Thomas Soucek; Barbara Blouw
Journal:  Eur J Neurosci       Date:  2009-03-23       Impact factor: 3.386

10.  Changes in proteasome structure and function caused by HAMLET in tumor cells.

Authors:  Lotta Gustafsson; Sonja Aits; Patrik Onnerfjord; Maria Trulsson; Petter Storm; Catharina Svanborg
Journal:  PLoS One       Date:  2009-04-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.